Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Gefapixant Formulations and Omeprazole Interaction in Healthy Subjects
NCT02492776Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gefapixant in chronic cough, sponsored by Merck & Co. Primary endpoints: Plasma concentration profiles of two different oral formulations of gefapixant at 12 hours and Plasma concentration profile of gefapixant following administration of omeprazole at 5.5 hours. Started Jul 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT02492776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492776.